Ipamorelin vs Sermorelin: GHSR- vs GHRH-Signalweg-Vergleich
Redaktion
Forschungsbereich
Diese lokalisierte Zusammenfassung bietet einen evidenzbasierten Überblick zu diesem Thema. Der vollständige Inhalt bleibt aus redaktionellen Konsistenzgründen auf Englisch.
Ipamorelin vs Sermorelin: Two Routes to GH-Axis Stimulation
Ipamorelin and sermorelin both engage growth-hormone-axis signaling, but they enter at different receptors. Ipamorelin is a ghrelin receptor (GHSR-1a) agonist. Sermorelin is a GHRH analog that acts upstream on pituitary GHRH receptors. Same endocrine output, different signaling checkpoints.
Side-by-Side
| Property | Ipamorelin | Sermorelin |
|---|---|---|
| Primary Target Receptor | GHSR-1a (ghrelin receptor) | GHRH receptor (pituitary) |
| Class | GH secretagogue peptide | Synthetic GHRH analog |
| Typical Research Framing | Pulse triggering via ghrelin pathway | Physiologic pituitary signaling support |
| Common Pairing Strategy | Often paired with GHRH analogs | Often paired with GHSR agonists |
| Focus in Protocol Design | Pulse amplitude and timing response | Axis regulation and baseline support |
Different Receptors, Same Endocrine Axis
Sermorelin works through GHRH-receptor pathways on pituitary somatotrophs — it is a fragment analog of endogenous GHRH. Ipamorelin activates GHSR-1a (the ghrelin receptor) to stimulate GH pulse release through a separate route. Co-activation of these two pathways can produce additive pulse behavior without forcing a single receptor system to carry the full signaling burden, which is why the pair appears so often in stack protocols.
A distinguishing feature of ipamorelin (versus older GHRPs like GHRP-6 and GHRP-2) is its selectivity: less activity at non-GH axes, and consequently less appetite or cortisol confounding in study interpretation.
How to Select the Right Comparator
Let receptor intent lead selection:
- Choose sermorelin as anchor when modeling GHRH-like pituitary stimulation with emphasis on endocrine-physiology alignment.
- Choose ipamorelin as anchor when studying ghrelin-pathway pulse dynamics or stack-response analysis.
In both cases, observed outcomes depend on circadian timing, baseline IGF-1, and protocol duration — these factors shape results independent of compound identity. See the CJC / Mod GRF / sermorelin family guide and ipamorelin vs CJC-1295 comparison for related framings.
Bottom Line
Ipamorelin and sermorelin are not interchangeable — they hit different receptors. They are often complementary because those receptors converge on the same pulse output. Good research design treats this as a pathway question first, and a dosing question second.
Educational content only. Not medical advice.
Evidenz & Quellen
Peer-Review-Referenzen zu den zugehörigen Peptiden. So lassen sich Aussagen leichter prüfen und zitieren.
Ipamorelin, the first selective growth hormone secretagogue
Ipamorelin • Raun K, et al. • Eur J Endocrinol (1998)
DOI: 10.1530/eje.0.1390552Sermorelin: a growth hormone-releasing hormone analog
Sermorelin • Thorner MO, et al. • J Clin Endocrinol Metab (1993)
DOI: 10.1210/jcem.77.5.8077320Hexarelin: a growth hormone-releasing peptide
Hexarelin • Deghenghi R, et al. • J Endocrinol Invest (1994)
DOI: 10.1007/BF03347720In der Bibliothek
FAQ — Antworten zuerst
Kurze Fragen und Antworten fĂĽr Lesbarkeit und Suchmaschinen.
Is ipamorelin the same as sermorelin?
No. Ipamorelin is primarily a ghrelin receptor (GHSR-1a) agonist. Sermorelin is a GHRH analog. Both can increase GH-axis activity, but through different receptors and for different research purposes.
Can they be combined in a research protocol?
Yes. Combination is common in GH-axis research because GHSR and GHRH signaling can be complementary. Researchers should still control for timing, dosing strategy, and endpoint definition.
Weiter entdecken
Forschungspeptide mit Fremdtests und Analysezertifikat.
Shop Peptides